Symbols / GKOS Stock $137.72 +1.00% Glaukos Corporation

Healthcare • Medical Devices • United States • NYQ
GKOS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Thomas William Burns
Exch · Country NYQ · United States
Market Cap 8.09B
Enterprise Value 7.83B
Income -189.33M
Sales 551.35M
FCF (ttm) 6.09M
Book/sh 11.50
Cash/sh 4.71
Employees 1,094
Insider 10d —
IPO Jun 25, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 287.91
PEG —
P/S 14.67
P/B 11.98
P/C —
EV/EBITDA -177.06
EV/Sales 14.21
Quick Ratio 4.43
Current Ratio 5.43
Debt/Eq 15.78
LT Debt/Eq —
EPS (ttm) -3.30
EPS next Y 0.48
EPS Growth —
Revenue Growth 41.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-29
ROA -5.78%
ROE -26.39%
ROIC —
Gross Margin 78.08%
Oper. Margin -13.19%
Profit Margin -34.34%
Shs Outstand 58.73M
Shs Float 57.72M
Insider Own 3.58%
Instit Own 99.26%
Short Float 6.70%
Short Ratio 4.58
Short Interest 3.23M
52W High 146.75
vs 52W High -6.15%
52W Low 73.16
vs 52W Low 88.24%
Beta 0.95
Impl. Vol. 57.42%
Rel Volume 0.17
Avg Volume 767.81K
Volume 133.35K
Target (mean) $151.08
Tgt Median $149.00
Tgt Low $136.00
Tgt High $170.00
# Analysts 12
Recom Strong_buy
Prev Close $136.36
Price $137.72
Change 1.00%
About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$151.08
Mean price target
2. Current target
$137.72
Latest analyst target
3. DCF / Fair value
$1.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$137.72
Low
$136.00
High
$170.00
Mean
$151.08

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-30 main JP Morgan Overweight → Overweight $140
2026-04-30 main Citigroup Buy → Buy $140
2026-04-30 main Wells Fargo Overweight → Overweight $138
2026-04-30 main Needham Buy → Buy $136
2026-04-30 main BTIG Buy → Buy $141
2026-02-18 main Wells Fargo Overweight → Overweight $135
2026-02-18 main Needham Buy → Buy $127
2026-02-18 reit BTIG Buy → Buy $131
2026-01-28 main BTIG Buy → Buy $131
2026-01-22 main Stifel Buy → Buy $160
2026-01-14 reit Needham Buy → Buy $125
2026-01-02 main Stephens & Co. Overweight → Overweight $145
2026-01-02 reit BTIG Buy → Buy $116
2025-12-23 main UBS Buy → Buy $145
2025-12-18 main Truist Securities Buy → Buy $145
2025-12-11 main Citigroup Buy → Buy $125
2025-12-09 main Needham Buy → Buy $125
2025-10-30 main JP Morgan Overweight → Overweight $120
2025-10-30 main Citigroup Buy → Buy $113
2025-10-30 main Wells Fargo Overweight → Overweight $122
News
RSS: Latest GKOS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 GILLIAM JOSEPH E. President — 19,573 $143.54 $2,809,508
2026-05-01 WEN LEANA Director — 1,700 $143.35 $243,695
2026-04-30 THURMAN ALEX R. Chief Financial Officer — 10,000 $38.68 $386,800
2026-04-30 THURMAN ALEX R. Chief Financial Officer — 10,000 $140.00 $1,400,000
2026-04-10 NAVRATIL TOMAS Officer — 2,093 $116.72 $246,175
2026-04-01 BURNS THOMAS WILLIAM Chief Executive Officer — 180,308 $0.00 $0
2026-03-25 BURNS THOMAS WILLIAM Chief Executive Officer — 23,564 $0.00 $0
2026-03-25 GILLIAM JOSEPH E. President — 23,621 $0.00 $0
2026-03-25 THURMAN ALEX R. Chief Financial Officer — 3,303 $0.00 $0
2026-03-25 NAVRATIL TOMAS Officer — 32,781 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
507.44
+32.33%
383.48
+21.85%
314.71
+11.26%
282.86
Operating Revenue
507.44
+32.33%
383.48
+21.85%
314.71
+11.26%
282.86
Cost Of Revenue
224.68
+138.95%
94.03
+24.42%
75.58
+9.56%
68.98
Reconciled Cost Of Revenue
224.68
+138.95%
94.03
+24.42%
75.58
+9.56%
68.98
Gross Profit
282.76
-2.31%
289.45
+21.04%
239.14
+11.81%
213.88
Operating Expense
482.36
+21.32%
397.59
+9.58%
362.84
+14.75%
316.20
Research And Development
150.61
+10.40%
136.43
-1.69%
138.77
+12.57%
123.27
Selling General And Administration
331.75
+27.03%
261.17
+16.56%
224.07
+16.14%
192.93
Total Expenses
707.04
+43.82%
491.62
+12.14%
438.41
+13.82%
385.18
Operating Income
-199.60
-84.58%
-108.14
+12.58%
-123.70
-20.90%
-102.31
Total Operating Income As Reported
-199.60
-63.12%
-122.37
+4.92%
-128.70
-56.35%
-82.31
EBITDA
-146.06
-52.72%
-95.64
-16.47%
-82.12
-68.40%
-48.76
Normalized EBITDA
-146.06
-79.42%
-81.41
-5.57%
-77.12
-12.15%
-68.76
Reconciled Depreciation
42.34
+6.07%
39.92
+5.12%
37.98
+5.65%
35.95
EBIT
-188.41
-38.98%
-135.56
-12.88%
-120.09
-41.77%
-84.71
Total Unusual Items
0.00
+100.00%
-14.23
-184.58%
-5.00
-125.00%
20.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-14.23
-184.58%
-5.00
-125.00%
20.00
Special Income Charges
0.00
+100.00%
-14.23
-184.58%
-5.00
-125.00%
20.00
Other Special Charges
—
14.23
+184.58%
5.00
+125.00%
-20.00
Net Income
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Pretax Income
-193.04
-32.58%
-145.60
-8.88%
-133.73
-35.86%
-98.43
Net Non Operating Interest Income Expense
6.08
+470.80%
1.06
+123.83%
-4.47
+60.61%
-11.35
Interest Expense Non Operating
4.63
-53.83%
10.04
-26.36%
13.63
-0.63%
13.72
Net Interest Income
6.08
+470.80%
1.06
+123.83%
-4.47
+60.61%
-11.35
Interest Expense
4.63
-53.83%
10.04
-26.36%
13.63
-0.63%
13.72
Interest Income Non Operating
10.71
-3.52%
11.11
+21.18%
9.16
+285.85%
2.38
Interest Income
10.71
-3.52%
11.11
+21.18%
9.16
+285.85%
2.38
Other Income Expense
0.48
+101.24%
-38.53
-593.22%
-5.56
-136.50%
15.23
Other Non Operating Income Expenses
0.48
+101.97%
-24.30
-4254.84%
-0.56
+88.30%
-4.77
Tax Provision
-5.35
-794.03%
0.77
-17.45%
0.93
+21.93%
0.77
Tax Rate For Calcs
0.00
-86.67%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-2.99
-184.58%
-1.05
-125.00%
4.20
Net Income Including Noncontrolling Interests
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Net Income From Continuing Operation Net Minority Interest
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Net Income From Continuing And Discontinued Operation
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Net Income Continuous Operations
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Normalized Income
-187.69
-38.90%
-135.13
-3.38%
-130.71
-13.67%
-115.00
Net Income Common Stockholders
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Diluted EPS
-3.28
-18.41%
-2.77
+0.36%
-2.78
-33.01%
-2.09
Basic EPS
-3.28
-18.41%
-2.77
+0.36%
-2.78
-33.01%
-2.09
Basic Average Shares
57.19
+8.41%
52.76
+8.92%
48.43
+2.08%
47.44
Diluted Average Shares
57.19
+8.41%
52.76
+8.92%
48.43
+2.08%
47.44
Diluted NI Availto Com Stockholders
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
893.49
-8.34%
974.76
+3.65%
940.41
-6.18%
1,002.38
Current Assets
474.98
+5.60%
449.79
+13.74%
395.46
-10.90%
443.86
Cash Cash Equivalents And Short Term Investments
278.76
-12.59%
318.92
+7.95%
295.43
-16.24%
352.69
Cash And Cash Equivalents
90.81
-46.46%
169.63
+81.48%
93.47
-21.80%
119.53
Other Short Term Investments
187.95
+25.89%
149.29
-26.08%
201.96
-13.38%
233.17
Receivables
108.61
+78.80%
60.74
+52.43%
39.85
+10.47%
36.07
Accounts Receivable
108.61
+78.80%
60.74
+52.43%
39.85
+10.47%
36.07
Gross Accounts Receivable
116.97
+89.22%
61.82
+50.59%
41.05
+9.99%
37.32
Allowance For Doubtful Accounts Receivable
-8.36
-679.12%
-1.07
+10.66%
-1.20
+3.92%
-1.25
Inventory
63.56
+10.20%
57.68
+37.37%
41.99
+10.95%
37.84
Raw Materials
25.39
+31.22%
19.35
+55.82%
12.42
-8.73%
13.60
Work In Process
15.14
+3.23%
14.66
+13.93%
12.87
+22.63%
10.49
Finished Goods
23.04
-2.65%
23.67
+41.73%
16.70
+21.52%
13.74
Prepaid Assets
—
—
—
—
Other Current Assets
24.05
+93.11%
12.46
-31.54%
18.19
+5.47%
17.25
Total Non Current Assets
418.50
-20.28%
524.96
-3.67%
544.95
-2.43%
558.52
Net PPE
184.18
+8.38%
169.94
-2.64%
174.54
+4.62%
166.83
Gross PPE
239.72
+11.75%
214.51
+2.63%
209.01
+7.71%
194.05
Accumulated Depreciation
-55.54
-24.60%
-44.57
-29.29%
-34.48
-26.64%
-27.22
Properties
0.00
0.00
0.00
0.00
Land And Improvements
17.20
+143.29%
7.07
+0.00%
7.07
+0.00%
7.07
Buildings And Improvements
6.67
+663.62%
0.87
+0.00%
0.87
+0.00%
0.87
Machinery Furniture Equipment
14.80
+11.88%
13.23
+8.49%
12.19
+16.26%
10.49
Construction In Progress
11.90
+47.15%
8.09
-53.47%
17.38
-2.77%
17.88
Other Properties
107.32
+2.93%
104.27
+3.06%
101.17
+4.16%
97.13
Leases
81.83
+1.04%
80.99
+15.15%
70.33
+16.02%
60.62
Goodwill And Other Intangible Assets
208.63
-36.70%
329.58
-5.59%
349.09
-6.66%
374.00
Goodwill
66.71
+0.87%
66.13
+0.00%
66.13
+0.00%
66.13
Other Intangible Assets
141.92
-46.13%
263.44
-6.90%
282.96
-8.09%
307.87
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
25.69
+0.96%
25.45
+19.33%
21.32
+20.54%
17.69
Total Liabilities Net Minority Interest
237.33
+14.20%
207.82
-56.58%
478.65
+1.33%
472.38
Current Liabilities
101.28
+34.81%
75.12
+1.50%
74.01
+2.29%
72.36
Payables And Accrued Expenses
73.14
+45.53%
50.26
-5.93%
53.43
-3.11%
55.14
Payables
27.71
+91.64%
14.46
+7.60%
13.44
-6.69%
14.40
Accounts Payable
24.62
+89.04%
13.03
-3.08%
13.44
-6.69%
14.40
Current Accrued Expenses
45.43
+26.91%
35.80
-10.48%
39.99
-1.84%
40.74
Pensionand Other Post Retirement Benefit Plans Current
28.13
+13.13%
24.87
+20.78%
20.59
+19.57%
17.22
Total Tax Payable
3.09
+115.25%
1.44
—
—
Total Non Current Liabilities Net Minority Interest
136.06
+2.53%
132.70
-67.20%
404.63
+1.15%
400.02
Long Term Debt And Capital Lease Obligation
103.88
+0.46%
103.40
-73.05%
383.74
+0.33%
382.48
Long Term Debt
—
—
282.77
+0.49%
281.40
Long Term Capital Lease Obligation
103.88
+0.46%
103.40
+2.41%
100.97
-0.11%
101.08
Non Current Deferred Liabilities
0.44
-93.63%
6.93
-3.02%
7.14
-1.65%
7.26
Non Current Deferred Taxes Liabilities
0.44
-93.63%
6.93
-3.02%
7.14
-1.65%
7.26
Other Non Current Liabilities
31.74
+41.87%
22.37
+62.69%
13.75
+33.80%
10.28
Stockholders Equity
656.15
-14.44%
766.93
+66.09%
461.77
-12.88%
530.00
Common Stock Equity
656.15
-14.44%
766.93
+66.09%
461.77
-12.88%
530.00
Capital Stock
0.06
+3.57%
0.06
+14.29%
0.05
+2.08%
0.05
Common Stock
0.06
+3.57%
0.06
+14.29%
0.05
+2.08%
0.05
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
57.54
+1.89%
56.47
+14.90%
49.15
+2.86%
47.78
Ordinary Shares Number
57.51
+1.89%
56.44
+14.91%
49.12
+2.86%
47.75
Treasury Shares Number
0.03
+0.00%
0.03
+0.00%
0.03
+0.00%
0.03
Additional Paid In Capital
1,586.06
+5.05%
1,509.83
+42.47%
1,059.75
+6.24%
997.47
Retained Earnings
-933.13
-25.18%
-745.44
-24.43%
-599.07
-29.00%
-464.41
Gains Losses Not Affecting Retained Earnings
3.30
+26.31%
2.62
+124.46%
1.17
+139.16%
-2.98
Treasury Stock
0.13
+0.00%
0.13
+0.00%
0.13
+0.00%
0.13
Other Equity Adjustments
3.30
+26.31%
2.62
+124.46%
1.17
+139.16%
-2.98
Total Equity Gross Minority Interest
656.15
-14.44%
766.93
+66.09%
461.77
-12.88%
530.00
Total Capitalization
656.15
-14.44%
766.93
+3.01%
744.54
-8.24%
811.40
Working Capital
373.71
-0.26%
374.67
+16.56%
321.45
-13.47%
371.50
Invested Capital
656.15
-14.44%
766.93
+3.01%
744.54
-8.24%
811.40
Total Debt
103.88
+0.46%
103.40
-73.05%
383.74
+0.33%
382.48
Net Debt
—
—
189.31
+16.95%
161.88
Capital Lease Obligations
103.88
+0.46%
103.40
+2.41%
100.97
-0.11%
101.08
Net Tangible Assets
447.53
+2.33%
437.35
+288.15%
112.68
-27.77%
156.00
Tangible Book Value
447.53
+2.33%
437.35
+288.15%
112.68
-27.77%
156.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-14.79
+75.88%
-61.32
-6.16%
-57.76
-74.59%
-33.08
Cash Flow From Continuing Operating Activities
-14.79
+75.88%
-61.32
-6.16%
-57.76
-74.59%
-33.08
Net Income From Continuing Operations
-187.69
-28.23%
-146.37
-8.70%
-134.66
-35.75%
-99.19
Depreciation Amortization Depletion
42.34
+6.07%
39.92
+5.12%
37.98
+5.65%
35.95
Depreciation
15.22
-0.03%
15.22
+16.49%
13.07
+18.42%
11.03
Amortization Cash Flow
27.13
+9.83%
24.70
-0.85%
24.91
+0.00%
24.91
Depreciation And Amortization
42.34
+6.07%
39.92
+5.12%
37.98
+5.65%
35.95
Amortization Of Intangibles
27.13
+9.83%
24.70
-0.85%
24.91
+0.00%
24.91
Other Non Cash Items
1.78
-93.85%
28.99
+290.64%
7.42
+243.93%
2.16
Stock Based Compensation
63.22
+25.91%
50.21
+15.34%
43.53
+12.88%
38.56
Provisionand Write Offof Assets
8.72
+1426.80%
0.57
+58.17%
0.36
—
Asset Impairment Charge
115.51
+2496.36%
4.45
0.00
0.00
Deferred Tax
-6.49
-2903.24%
-0.22
-80.00%
-0.12
-122.22%
-0.05
Deferred Income Tax
-6.49
-2903.24%
-0.22
-80.00%
-0.12
-122.22%
-0.05
Operating Gains Losses
-1.18
-122.69%
5.22
+6097.70%
-0.09
-103.92%
2.22
Net Foreign Currency Exchange Gain Loss
-1.22
-126.32%
4.62
+571.43%
-0.98
-143.71%
2.24
Gain Loss On Sale Of PPE
0.03
-94.65%
0.60
-33.03%
0.89
+3820.83%
-0.02
Change In Working Capital
-48.02
-19.92%
-40.05
-281.60%
-10.49
+21.97%
-13.45
Change In Receivables
-53.02
-142.38%
-21.88
-495.40%
-3.67
-17.08%
-3.14
Changes In Account Receivables
-53.02
-142.38%
-21.88
-495.40%
-3.67
-17.08%
-3.14
Change In Inventory
-7.70
+60.40%
-19.45
-262.87%
-5.36
+65.36%
-15.47
Change In Prepaid Assets
-6.12
-586.34%
1.26
+145.53%
-2.77
-60.76%
-1.72
Change In Payables And Accrued Expense
18.82
+89538.10%
0.02
-98.39%
1.30
-81.90%
7.21
Change In Other Current Assets
—
-2.08
-10.37%
-1.88
-473.17%
-0.33
Investing Cash Flow
-77.61
-262.27%
47.83
+239.35%
14.10
-68.52%
44.78
Cash Flow From Continuing Investing Activities
-77.61
-262.27%
47.83
+239.35%
14.10
-68.52%
44.78
Net PPE Purchase And Sale
-24.27
-287.62%
-6.26
+69.07%
-20.25
+32.76%
-30.11
Purchase Of PPE
-24.27
-285.29%
-6.30
+68.89%
-20.25
+33.10%
-30.27
Sale Of PPE
0.00
-100.00%
0.04
0.00
-100.00%
0.15
Capital Expenditure
-24.27
-285.29%
-6.30
+68.89%
-20.25
+33.10%
-30.27
Net Investment Purchase And Sale
-35.35
-161.76%
57.24
+52.60%
37.51
-49.91%
74.89
Purchase Of Investment
-232.29
-22.29%
-189.96
+28.48%
-265.59
-340.71%
-60.26
Sale Of Investment
196.94
-20.33%
247.20
-18.44%
303.10
+124.26%
135.16
Net Business Purchase And Sale
-12.44
0.00
0.00
—
Purchase Of Business
-12.44
0.00
0.00
—
Net Other Investing Changes
-5.55
-76.13%
-3.15
+0.60%
-3.17
—
Financing Cash Flow
11.89
-87.02%
91.54
+508.56%
15.04
+140.63%
6.25
Cash Flow From Continuing Financing Activities
11.89
-87.02%
91.54
+508.56%
15.04
+140.63%
6.25
Net Issuance Payments Of Debt
-1.12
+29.45%
-1.59
-123.49%
-0.71
-34.91%
-0.53
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-1.12
+29.45%
-1.59
-123.49%
-0.71
-34.91%
-0.53
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-1.12
+29.45%
-1.59
-123.49%
-0.71
-34.91%
-0.53
Net Long Term Debt Issuance
-1.12
+29.45%
-1.59
-123.49%
-0.71
-34.91%
-0.53
Proceeds From Stock Option Exercised
21.14
-54.80%
46.76
+145.78%
19.03
+106.65%
9.21
Net Other Financing Charges
-8.13
-117.54%
46.37
+1516.62%
-3.27
-34.75%
-2.43
Changes In Cash
-80.52
-203.16%
78.05
+372.71%
-28.62
-259.48%
17.95
Effect Of Exchange Rate Changes
0.80
+126.65%
-3.02
-324.98%
1.34
+191.35%
-1.47
Beginning Cash Position
174.36
+75.55%
99.32
-21.55%
126.60
+14.96%
110.12
End Cash Position
94.65
-45.72%
174.36
+75.55%
99.32
-21.55%
126.60
Free Cash Flow
-39.06
+42.23%
-67.62
+13.32%
-78.01
-23.14%
-63.35
Interest Paid Supplemental Data
4.21
-54.27%
9.21
-24.84%
12.25
-0.70%
12.34
Income Tax Paid Supplemental Data
0.95
-30.22%
1.36
-12.65%
1.56
+198.28%
0.52
Amortization Of Securities
-2.98
+26.30%
-4.04
-140.06%
-1.69
-330.51%
0.73
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category